Found: 65
Select item for more details and to access through your institution.
Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics.
- Published in:
- EP: Europace, 2013, v. 15, n. 7, p. 1042, doi. 10.1093/europace/eut018
- By:
- Publication type:
- Article
Landscape analysis for a neonatal disease progression model of bronchopulmonary dysplasia: Leveraging clinical trial experience and real-world data.
- Published in:
- Frontiers in Pharmacology, 2022, v. 13, p. 1, doi. 10.3389/fphar.2022.988974
- By:
- Publication type:
- Article
Elements for Adequate Informed Consent in the Surgical Context.
- Published in:
- World Journal of Surgery, 2014, v. 38, n. 7, p. 1594, doi. 10.1007/s00268-014-2588-x
- By:
- Publication type:
- Article
Economic Burden and Disparities in Healthcare Resource Use Among Adult Patients with Cardiac Arrhythmia.
- Published in:
- Applied Health Economics & Health Policy, 2014, v. 12, n. 1, p. 59, doi. 10.1007/s40258-013-0070-9
- By:
- Publication type:
- Article
Development of Clinical Trial Simulation Tools for Alzheimer's Disease through the Critical Path for Alzheimer's Disease (CPAD) Consortium.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 21, p. 1, doi. 10.1002/alz.074773
- By:
- Publication type:
- Article
Towards a standardized pipeline for tau PET analysis under a GAAIN/LONI and CPAD collaborative framework.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.076995
- By:
- Publication type:
- Article
Recommendations to address key recruitment challenges of Alzheimer's disease clinical trials.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 2, p. 696, doi. 10.1002/alz.12737
- By:
- Publication type:
- Article
ALZ‐NET: Using Real World Evidence to Inform the Future of Alzheimer's Treatment and Care.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.069542
- By:
- Publication type:
- Article
Development of Clinical Trial Simulation Tools for Alzheimer's Disease through the Critical Path for Alzheimer's Disease (CPAD) Consortium.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.059971
- By:
- Publication type:
- Article
Correlations and associations between fluid‐based and morphometric imaging biomarkers through interrogation and integration of data and analysis across two data platforms.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 6, p. 1, doi. 10.1002/alz.060679
- By:
- Publication type:
- Article
The Critical Path for Alzheimer's Disease (CPAD) Consortium: A platform for pre‐competitive data sharing, standardization, and analysis to support quantitative tools for AD drug development.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.051903
- By:
- Publication type:
- Article
Graphical user interfaces for regulatory‐endorsed quantitative drug development tools in Alzheimer's disease: Human/Trial design.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.044029
- By:
- Publication type:
- Article
The Critical Path for Alzheimer's Disease (CPAD): Pre‐competitive data sharing and generation of innovative high‐impact quantitative tools to support Alzheimer's disease drug development: Human/Trial design.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.043919
- By:
- Publication type:
- Article
Generation of a comprehensive disease progression model across the Alzheimer's disease continuum: Human/Trial design.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.043258
- By:
- Publication type:
- Article
P4‐253: THE CRITICAL PATH FOR ALZHEIMER'S DISEASE (CPAD) CONSORTIUM – A PRE‐COMPETITIVE, GLOBAL, INTEGRATED, AND STANDARDIZED ALZHEIMER DISEASE CLINICAL TRIAL DATA SHARING REPOSITORY TO SUPPORT AD DRUG DEVELOPMENT.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P1376, doi. 10.1016/j.jalz.2019.06.3922
- By:
- Publication type:
- Article
P4‐090: THE CRITICAL PATH FOR ALZHEIMER'S DISEASE (CPAD) CONSORTIUM: FACILITATING RAPID DATA AND INFORMATION SHARING BY ESTABLISHING A SUSTAINABLE, INTEGRATED, AND STANDARDIZED PLATFORM ADVANCING KNOWLEDGE TO ENABLE EXPEDITED DRUG DEVELOPMENT.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1470, doi. 10.1016/j.jalz.2018.06.2493
- By:
- Publication type:
- Article
P3‐031: THE CRITICAL PATH FOR ALZHEIMER'S DISEASE: HIPPOCAMPAL VOLUME AS AN ENRICHMENT BIOMARKER IN TRIALS OF PATIENTS WITH MILD COGNITIVE IMPAIRMENT.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P1076, doi. 10.1016/j.jalz.2018.06.1386
- By:
- Publication type:
- Article
THE COALITION AGAINST MAJOR DISEASES: TOWARD U.S. FDA QUALIFICATION OF HIPPOCAMPAL VOLUME AS A BIOMARKER FOR ENRICHMENT IN CLINICAL TRIALS FOR PRE-DEMENTIA STAGES OF ALZHEIMER'S DISEASE.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2017, v. 13, p. P1259, doi. 10.1016/j.jalz.2017.06.1878
- By:
- Publication type:
- Article
Big data to smart data in Alzheimer's disease: Real-world examples of advanced modeling and simulation.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, n. 9, p. 1022, doi. 10.1016/j.jalz.2016.05.005
- By:
- Publication type:
- Article
Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2016, v. 12, n. 9, p. 1014, doi. 10.1016/j.jalz.2016.04.008
- By:
- Publication type:
- Article
Development of a unified clinical trial database for Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 10, p. 1212, doi. 10.1016/j.jalz.2014.11.005
- By:
- Publication type:
- Article
Quantifying the placebo effect through modeling and simulation.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 7, p. P210, doi. 10.1016/j.jalz.2015.07.218
- By:
- Publication type:
- Article
The path to regulatory qualification of cerebrospinal fluid biomarkers as enrichment tools in clinical trials of patients with early Alzheimer’s disease: For the coalition against major diseases.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2015, v. 11, n. 7, p. P296, doi. 10.1016/j.jalz.2015.07.406
- By:
- Publication type:
- Article
Advancement of a drug-disease trial model for Alzheimer's disease through a regulatory science path: The CAMD experience
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Model-based analysis to support strategic decision-making: A case study from the development of a 5HT6 antagonist for the treatment of Alzheimer's disease
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Integration of data for a model-based longitudinal meta-analysis of cognitive changes in mild and moderate Alzheimer's patients
- Published in:
- 2012
- By:
- Publication type:
- Abstract
Recommendations to Optimize the Use of Volumetric MRI in Huntington's Disease Clinical Trials.
- Published in:
- Frontiers in Neurology, 2021, v. 12, p. 1, doi. 10.3389/fneur.2021.712565
- By:
- Publication type:
- Article
Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin.
- Published in:
- AAPS Journal, 2018, v. 20, n. 3, p. 1, doi. 10.1208/s12248-018-0199-4
- By:
- Publication type:
- Article
Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Nonclinical models for antituberculosis drug development: a landscape analysis.
- Published in:
- 2015
- By:
- Publication type:
- Journal Article
Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease AMeta-analysis.
- Published in:
- JAMA Neurology, 2017, v. 74, n. 10, p. 1178, doi. 10.1001/jamaneurol.2017.2188
- By:
- Publication type:
- Article
Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular Dystrophy.
- Published in:
- PLoS Currents, 2017, p. 59, doi. 10.1371/currents.md.83071bbd728982f2f1073f4950e03586
- By:
- Publication type:
- Article
Time to Replace Bazett's QT-Correction.
- Published in:
- Pacing & Clinical Electrophysiology, 2009, v. 32, n. 11, p. 1379, doi. 10.1111/j.1540-8159.2009.02513.x
- By:
- Publication type:
- Article
Correlations Between the Hollow Fiber Model of Tuberculosis and Therapeutic Events in Tuberculosis Patients: Learn and Confirm.
- Published in:
- Clinical Infectious Diseases, 2015, v. 61, p. S18, doi. 10.1093/cid/civ426
- By:
- Publication type:
- Article
Strategic Regulatory Evaluation and Endorsement of the Hollow Fiber Tuberculosis System as a Novel Drug Development Tool.
- Published in:
- Clinical Infectious Diseases, 2015, v. 61, p. S5, doi. 10.1093/cid/civ424
- By:
- Publication type:
- Article
Systematic Analysis of Hollow Fiber Model of Tuberculosis Experiments.
- Published in:
- Clinical Infectious Diseases, 2015, v. 61, p. S10, doi. 10.1093/cid/civ425
- By:
- Publication type:
- Article
Forecasting Accuracy of the Hollow Fiber Model of Tuberculosis for Clinical Therapeutic Outcomes.
- Published in:
- Clinical Infectious Diseases, 2015, v. 61, p. S25, doi. 10.1093/cid/civ427
- By:
- Publication type:
- Article
A Modern Curriculum for Training Scientists in Model‐Informed Drug Development: Progress Report on FDA Grant to Train Regulatory Scientists.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 2, p. 289, doi. 10.1002/cpt.3039
- By:
- Publication type:
- Article
Unlocking the Capabilities of Large Language Models for Accelerating Drug Development.
- Published in:
- Clinical Pharmacology & Therapeutics, 2024, v. 116, n. 1, p. 38, doi. 10.1002/cpt.3279
- By:
- Publication type:
- Article
T1dCteGui: A User‐Friendly Clinical Trial Enrichment Tool to Optimize T1D Prevention Studies by Leveraging AI/ML Based Synthetic Patient Population.
- Published in:
- Clinical Pharmacology & Therapeutics, 2023, v. 114, n. 3, p. 704, doi. 10.1002/cpt.2976
- By:
- Publication type:
- Article
Leveraging Real‐World Data for EMA Qualification of a Model‐Based Biomarker Tool to Optimize Type‐1 Diabetes Prevention Studies.
- Published in:
- Clinical Pharmacology & Therapeutics, 2022, v. 111, n. 5, p. 1133, doi. 10.1002/cpt.2559
- By:
- Publication type:
- Article
Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 4, p. 796, doi. 10.1002/cpt.1782
- By:
- Publication type:
- Article
Open Data for Clinical Pharmacology.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 4, p. 703, doi. 10.1002/cpt.1779
- By:
- Publication type:
- Article
Hippocampal Neuroimaging‐Informed Clinical Trial Enrichment Tool for Amnestic Mild Cognitive Impairment Using Open Data.
- Published in:
- Clinical Pharmacology & Therapeutics, 2020, v. 107, n. 4, p. 903, doi. 10.1002/cpt.1766
- By:
- Publication type:
- Article
Type 1 diabetes prevention clinical trial simulator: Case reports of model‐informed drug development tool.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2024, v. 13, n. 8, p. 1309, doi. 10.1002/psp4.13193
- By:
- Publication type:
- Article
Disease progression joint model predicts time to type 1 diabetes onset: Optimizing future type 1 diabetes prevention studies.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2023, v. 12, n. 7, p. 1016, doi. 10.1002/psp4.12973
- By:
- Publication type:
- Article
Development of a model‐based clinical trial simulation platform to optimize the design of clinical trials for Duchenne muscular dystrophy.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2022, v. 11, n. 3, p. 318, doi. 10.1002/psp4.12753
- By:
- Publication type:
- Article
Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2021, v. 10, n. 11, p. 1382, doi. 10.1002/psp4.12707
- By:
- Publication type:
- Article
Pharmacometrics as a Discipline Is Entering the “Industrialization” Phase: Standards, Automation, Knowledge Sharing, and Training Are Critical for Future Success.
- Published in:
- Journal of Clinical Pharmacology, 2010, v. 50, n. 9, p. 9S, doi. 10.1177/0091270010377788
- By:
- Publication type:
- Article
Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development.
- Published in:
- Journal of Pharmacokinetics & Pharmacodynamics, 2018, v. 45, n. 3, p. 457, doi. 10.1007/s10928-018-9580-2
- By:
- Publication type:
- Article